First Republic Investment Management Inc. bought a new stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) during the 4th quarter, HoldingsChannel reports. The firm bought 2,100 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Virtus Fund Advisers LLC bought a new position in Puma Biotechnology during the 4th quarter valued at about $955,000. Artal Group S.A. bought a new position in Puma Biotechnology during the 4th quarter valued at about $4,943,000. UBS Asset Management Americas Inc. lifted its stake in Puma Biotechnology by 11.1% during the 4th quarter. UBS Asset Management Americas Inc. now owns 18,400 shares of the biopharmaceutical company’s stock valued at $1,819,000 after acquiring an additional 1,837 shares during the period. BlackRock Inc. lifted its stake in Puma Biotechnology by 31.4% during the 4th quarter. BlackRock Inc. now owns 2,385,036 shares of the biopharmaceutical company’s stock valued at $235,763,000 after acquiring an additional 570,393 shares during the period. Finally, Eagle Asset Management Inc. bought a new position in Puma Biotechnology during the 4th quarter valued at about $28,918,000. Institutional investors and hedge funds own 94.53% of the company’s stock.
Several research firms have issued reports on PBYI. Stifel Nicolaus set a $95.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Friday. BidaskClub cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Saturday, March 3rd. Barclays lowered their target price on shares of Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, March 2nd. Credit Suisse Group set a $106.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Friday, March 2nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of Puma Biotechnology from $138.00 to $91.00 and set a “buy” rating on the stock in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and an average price target of $103.11.
Shares of Puma Biotechnology Inc (PBYI) opened at $80.75 on Friday. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to analysts’ expectations of $20.83 million. During the same period in the previous year, the company earned ($1.22) EPS. research analysts expect that Puma Biotechnology Inc will post -3.86 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3253201/first-republic-investment-management-inc-buys-shares-of-2100-puma-biotechnology-inc-pbyi.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.